Michael L. Jackson, PhD, MPH, focuses on understanding how infectious diseases spread, and on designing and evaluating interventions such as vaccination programs. Dr. Jackson is the Kaiser Permanente Washington Health Research Institute (KPWHRI) principal investigator for the United States Influenza Vaccine Effectiveness (US Flu VE) Network. Using information from five sites across the country, including Kaiser Permanente Washington, this network aims to provide ongoing evaluations of the U.S. influenza vaccination program. Dr. Jackson uses data from this network to study influenza vaccine effectiveness, to estimate the burden of disease caused by influenza, and to advance the methodology of vaccine effectiveness studies.
In addition, Dr. Jackson is using data collected by the US Flu VE Network to build a simulation model for the spread of influenza, with a specific focus on understanding when new strains of the influenza virus can out-compete existing strains. This work, funded by the National Institutes of Health, aims to improve our ability to correctly choose which strains of the influenza virus to include in seasonal influenza vaccines. He also uses simulation models to predict the impact of vaccination programs on the spread of infectious diseases such as Haemophilus influenzae type b (Hib) and Neisseria meningitidis.
Dr. Jackson is a co-investigator on the Vaccine Safety Datalink (VSD) Project. The VSD, a collaboration among nine U.S. managed care organizations and the Centers for Disease Control and Prevention (CDC), is the world’s premier system for post-licensure studies of vaccine safety. As a VSD co-investigator, Dr. Jackson leads studies of the safety of childhood immunizations and develops methods for using managed care data for vaccine safety studies.
While studying for his PhD at the University of Washington, Dr. Jackson was a graduate research associate with KPWHRI from 2002 to 2007, and then a postdoctoral fellow at KPWHRI from 2007 to 2008. He then spent two years as an Epidemic Intelligence Service (EIS) officer with the CDC in Atlanta. As an EIS officer, Dr. Jackson helped lead investigations of whooping cough outbreaks and of the 2009 influenza pandemic. He also designed and oversaw an enhanced surveillance system for invasive Hib disease in the U.S. during the 2008–2009 shortage of Hib vaccines. He returned to KPWHRI as an assistant investigator in 2010. He is an affiliate associate professor at the University of Washington School of Public Health.
Newman KL, Rogers JH, McCulloch D, Wilcox N, Englund JA, Boeckh M, Uyeki TM, Jackson ML, Starita L, Hughes JP, Chu HY, Seattle Flu Study Investigators. Point-of-care molecular testing and antiviral treatment of influenza in residents of homeless shelters in Seattle, WA: study protocol for a stepped-wedge cluster-randomized controlled trial. Trials. 2020 Nov 23;21(1):956. doi: 10.1186/s13063-020-04871-5. PubMed
Emanuels A, Heimonen J, O’Hanlon J, Kim AE, Wilcox N, McCulloch DJ, Brandstetter E, Wolf CR, Logue JK, Han PD, Pfau B, Newman KL, Hughes JP, Jackson ML. Remote household observation for non-influenza respiratory viral illness. Clin Infect Dis. 2020 Nov 17:ciaa1719. doi: 10.1093/cid/ciaa1719. PubMed
Patel MM, Jackson ML, Ferdinands J. Postlicensure evaluation of COVID-19 vaccines. JAMA. 2020 Oct 16. doi: 10.1001/jama.2020.19328. Online ahead of print. PubMed
Greene DN, Jackson ML, Hillyard DR, Delgado JC, Schmidt RL. Decreasing median age of COVID-19 cases in the United States-changing epidemiology or changing surveillance? PLoS One. 2020 Oct 15;15(10):e0240783. doi: 10.1371/journal.pone.0240783. eCollection 2020. PubMed
Jackson ML. Low-impact social distancing interventions to mitigate local epidemics of SARS-CoV-2. Microbes Infect. 2020 Sep 22:S1286-4579(20)30159-3. doi: 10.1016/j.micinf.2020.09.006. [Epub ahead of print]. PubMed
Rogers JH, Link AC, McCulloch D, Brandstetter E, Newman KL, Jackson ML, Hughes JP, Englund JA, Boeckh M, Sugg N, Ilcisin M, Sibley TR, Fay K, Lee J, Han P, Truong M, Richardson M, Nickerson DA, Starita LM, Bedford T, Chu HY. Characteristics of COVID-19 in homeless shelters: a community-based surveillance study. Ann Intern Med. 2020 Sep 15. doi: 10.7326/M20-3799. Online ahead of print. PubMed
Balasubramani GK, Choi WS, Nowalk MP, Zimmerman RK, Monto AS, Martin ET, Belongia EA, McLean HQ, Gaglani M, Murthy K, Jackson ML, Jackson LA, Chung JR, Spencer S, Fry AM, Patel M, Flannery B; US Flu VE Network Investigators. Relative effectiveness of high dose versus standard dose influenza vaccines in older adult outpatients over four seasons, 2015-16 to 2018-19. Vaccine. 2020 Aug 12:S0264-410X(20)31032-X. doi: 10.1016/j.vaccine.2020.08.011. Online ahead of print. PubMed
Flannery B, Meece JK, Williams JV, Martin ET, Gaglani M, Jackson ML, Talbot HK. Systematic testing for influenza and COVID-19 among patients with respiratory illness. Clin Infect Dis. 2020 Jul 20:ciaa1023. doi: 10.1093/cid/ciaa1023. [Epub ahead of print]. PubMed
Jackson ML, Scott E, Kuypers J, Nalla AK, Roychoudury P, Chu HY. Epidemiology of respiratory syncytial virus across five influenza seasons among adults and children one year of age and older - Washington State, 2011/12 - 2015/16. LID - jiaa331 [pii] LID - 10.1093/infdis/jiaa331 [doi] J Infect Dis. 2020 Jun 19:jiaa331. doi: 10.1093/infdis/jiaa331 [Epub ahead of print] PubMed
Kim SS, Flannery B, Foppa IM, Chung JR, Nowalk MP, Zimmerman RK, Gaglani M, Monto AS, Martin ET, Belongia EA, McLean HQ, Jackson ML, Jackson LA, Patel M. Effects of prior season vaccination on current season vaccine effectiveness in the US Flu VE Network, 2012-13 through 2017-18. Clin Infect Dis. 2020 Jun 7:ciaa706. doi: 10.1093/cid/ciaa706. [Epub ahead of print]. PubMed
In a JAMA Viewpoint, Dr. Mike Jackson plans ahead to meet the challenges of continuing to evaluate new vaccines.
KPWHRI’s Michael L. Jackson, PhD, MPH, talks about influenza vaccine research in the age of the pandemic.
Dr. Mike Jackson has long studied the spread of flu and effectiveness of vaccination. And now… of COVID-19 too.
KPWHRI’s Dr. Michael Jackson describes how better testing will improve our ability to forecast the pandemic’s path.
WebMD, Sept. 2, 2020